Wells Fargo analyst Jim Birchenough maintained a Hold rating on Celgene (CELG) today. The company’s shares opened today at $87.86.
According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 19.9% and a 46.8% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Alder Biopharmaceuticals.
Celgene has an analyst consensus of Moderate Buy, with a price target consensus of $109.55, a 24.7% upside from current levels. In a report issued on December 21, BTIG also initiated coverage with a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $109.98 and a one-year low of $58.59. Currently, Celgene has an average volume of 6.54M.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CELG in relation to earlier this year. Most recently, in December 2018, Ernest Mario, a Director at CELG bought 8,600 shares for a total of $507,830.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company’s products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
